Updated:
Cabaletta Bio
Cabaletta Bio engineers CAAR T-cell therapies to eliminate disease-causing B-cells in autoimmune conditions, led by CEO Steven Nichtberger.
Cabaletta Bio
Cabaletta Bio was founded in 2017 to translate a platform conceived in the laboratory of Dr. Aimee Payne at the University of Pennsylvania. The scientific premise is narrow and deliberate: target only the pathogenic B-cells that produce disease-causing autoantibodies, preserving the rest of the immune system. Dr. Steven Nichtberger, a veteran of biotech development with roots at Tengion and as a longtime executive-in-residence, has led the company as CEO since its inception. The founding leadership team also includes Dr. Gwendolyn Binder, the president of science and technology who joined from the UPenn spinout process and now oversees the company's translational engine. The firm's lead asset, DSG3-CAART, entered the DesCAARTes clinical trial for mucosal pemphigus vulgaris and later a combination study designed to offer deeper, more durable B-cell depletion. A second program, MuSK-CAART, targets a subset of myasthenia gravis patients who fail conventional immunosuppression, operating under a similar antigen-specific killing logic. Both programs rely on an autologous CAR construct, manufactured at the patient level. Beyond CAARs, Cabaletta has expanded into a class of CD19-targeting CAR T therapies through an academic partnership, indicating a strategic appetite to cover both antigen-specific and broad B-cell depletion approaches. The geographic footprint is centered in Philadelphia with clinical sites in the eastern US. Cabaletta trades on Nasdaq under the ticker CABA and funds operations through equity financing rounds and venture debt; a secondary offering in the first half of 2024 aimed to extend the company's cash runway into mid-2026. The firm has not publicly disclosed partnership revenues from larger pharmaceutical collaborators, though its board includes veterans from the cell-therapy manufacturing and immunology sectors who bring technical-operational heft. In January 2025, the company received FDA alignment on a pivotal trial design for DSG3-CAART, shifting the asset into a registration-enabling phase. Cabaletta's architecture is distinct in autoimmune cell therapy: rather than repurpose a CD19 CAR that wipes the entire B-cell compartment, the CAAR platform engineers a cell to hunt one specific pathogenic clone. The difference is immunological precision versus immunosuppression, and it is structurally analogous to how CAR T originally outperformed chemotherapy in oncology — a narrower attack on the disease driver. The firm's dual-platform exposure, layering resettled CAAR programs with next-wave CD19 candidates, creates an internal hedge on which mechanism will prove clinically and commercially superior.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, PA, United States
Principals
Steven Nichtberger
President, Chief Executive Officer & Director
Gwendolyn Binder
President, Science & Technology
David Chang
Chief Medical Officer
Sector focus
Frequently asked questions
What is the differentiating scientific mechanism behind Cabaletta's CAAR platform?
The CAAR (chimeric autoantibody receptor) platform engineers a patient's T-cells to express a receptor that mimics the autoantigen targeted by pathogenic B-cells. When infused, the CAAR T-cells bind and kill only the B-cells that produce the disease-causing autoantibodies, leaving the rest of the immune system intact. The technology is built on research from the lab of Dr. Aimee Payne at the University of Pennsylvania.
Which clinical milestones has Cabaletta achieved for its lead program?
The mucosal pemphigus vulgaris program, DSG3-CAART, has advanced through the Phase 1 DesCAARTes trial and a subsequent combination dosing study. In January 2025, Cabaletta announced a Type B alignment with the FDA on a randomized, controlled pivotal trial design, clearing the path toward a potential Biologics License Application submission.
How does Cabaletta's approach differ from a CD19 CAR T for autoimmune disease?
A CD19 CAR T depletes the entire B-cell population, which can reset disease but leaves patients immunocompromised for an extended period. The CAAR T platform targets only the pathogenic B-cell subpopulation — for example, cells making anti-desmoglein 3 antibodies in pemphigus vulgaris — aiming to preserve protective humoral immunity while eliminating the disease.
What is the company's funding and liquidity position?
Cabaletta is publicly listed on Nasdaq under the symbol CABA and has funded itself through equity issuances, including a secondary offering completed between mid-2024 and early 2025 intended to extend its cash runway into 2026. It also raised capital previously through an initial public offering and has layered in venture debt facilities.
Who are the key scientific and operational leaders at Cabaletta?
Dr. Steven Nichtberger is the CEO and co-founder, bringing decades of biotech operating experience. Dr. Gwendolyn Binder, president of science and technology, co-founded the company out of the University of Pennsylvania and drives the translational strategy. Dr. David Chang joined as chief medical officer to lead clinical development across the autoimmune portfolio.
What autoimmune indications does Cabaletta target beyond pemphigus vulgaris?
The MuSK-CAART program targets MuSK myasthenia gravis, a rare neuromuscular junction disorder. The company also has a disclosed CD19 CAR T strategy that targets a broader B-cell-mediated autoimmune population, indicating a pipeline designed to cover different immunological mechanisms across a spectrum of autoimmune conditions.
How is the CAAR technology licensed, and what is the relationship with the University of Pennsylvania?
Cabaletta holds an exclusive license to the foundational CAAR intellectual property developed in the Payne Lab at the Perelman School of Medicine. The company continues an active sponsored research agreement with the university, a standard structure that anchors the translational pipeline and provides access to immunological expertise at one of the leading cell-therapy centers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: